|
1
|
Ottaviani G and Jaffe N: The epidemiology
of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Luetke A, Meyers PA, Lewis I and Juergens
H: Osteosarcoma treatment-where do we stand? A state of the art
review. Cancer Treat Rev. 40:523–532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laux CJ, Berzaczy G, Weber M, Lang S,
Dominkus M, Windhager R, Nöbauer-Huhmann IM and Funovics PT: Tumour
response of osteosarcoma to neoadjuvant chemotherapy evaluated by
magnetic resonance imaging as prognostic factor for outcome. Int
Orthop. 39:97–104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bentwich L, Avniel A, Karov Y, Aharonov R,
Gilad S, Barad O, Barzilai A, Einat P, Einav U, Meiri E, et al:
Identification of hundreds of conserved and nonconserved human
microRNAs. Nat Genet. 37:766–70. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Prasad R and Katiyar SK: Down-regulation
of miRNA-106b inhibits growth of melanoma cells by promoting
G1-phase cell cycle arrest and reactivation of p21/WAF1/Cip1
protein. Oncotarget. 5:10636–10649. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hayashita Y, Osada H, Tatematsu Y, Yamada
H, Yanagisawa K, Tomida S, Yatabe Y, Kawahara K, Sekido Y and
Takahashi T: A polycistronic microRNA cluster, miR-17-92, is
overexpressed in human lung cancers and enhances cell
proliferation. Cancer Res. 65:9628–9632. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu C, Peng K, Guo H, Ren X, Hu S, Cai Y,
Han Y, Ma L and Xu P: miR-18a-5p promotes cell invasion and
migration of osteosarcoma by directly targeting IRF2. Oncol Lett.
16:3150–3156. 2018.PubMed/NCBI
|
|
8
|
Wu D, Zhang H, Ji F and Ding W:
MicroRNA-17 promotes osteosarcoma cells proliferation and migration
and inhibits apoptosis by regulating SASH1 expression. Pathol Res
Pract. 215:115–120. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rehei AL, Zhang L, Fu YX, Mu WB, Yang DS,
Liu Y, Zhou SJ and Younusi A: MicroRNA-214 functions as an oncogene
in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol
Sci. 22:5156–5164. 2018.PubMed/NCBI
|
|
10
|
Wang X, Peng L, Gong X, Zhang X, Sun R and
Du J: miR-423-5p inhibits osteosarcoma proliferation and invasion
through directly targeting STMN1. Cell Physiol Biochem.
50:2249–2259. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen T, Li Y, Cao W and Liu Y: miR-491-5p
inhibits osteosarcoma cell proliferation by targeting PKM2. Oncol
Lett. 16:6472–6478. 2018.PubMed/NCBI
|
|
12
|
Wang WT, Qi Q, Zhao P, Li CY, Yin XY and
Yan RB: miR-590-3p is a novel microRNA which suppresses
osteosarcoma progression by targeting SOX9. Biomed Pharmacother.
107:1763–1769. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ye J, Yao Y, Song Q, Li S, Hu Z, Yu Y, Hu
C, Da X, Li H, Chen Q and Wang QK: Up-regulation of miR-95-3p in
hepatocellular carcinoma promotes tumorigenesis by targeting p21
expression. Sci Rep. 6:340342016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Zhang C, Hu L, He Y, Shi Z, Tang
S and Chen Y: Abnormal expression of miR-21 and miR-95 in cancer
stem-like cells is associated with radioresistance of lung cancer.
Cancer Invest. 33:165–171. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qin J, Teng JA, Zhu Z, Chen JX and Wu YY:
Glargine promotes human colorectal cancer cell proliferation via
upregulation of miR-95. Horm Metab Res. 47:861–865. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Allen-Rhoades W, Kurenbekova L,
Satterfield L, Parikh N, Fuja D, Shuck RL, Rainusso N, Trucco M,
Barkauskas DA, Jo E, et al: Cross-species identification of a
plasma microRNA signature for detection, therapeutic monitoring,
and prognosis in osteosarcoma. Cancer Med. 4:977–988. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang X, Taeb S, Jahangiri S, Emmenegger
U, Tran E, Bruce J, Mesci A, Korpela E, Vesprini D, Wong CS, et al:
miRNA-95 mediates radioresistance in tumors by targeting the
sphingolipid phosphatase SGPP1. Cancer Res. 73:6972–6986. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Qiu D, Han F and Zhuang H: MiR-499
rs3746444 polymorphism and hepatocellular carcinoma risk: A
meta-analysis. J Cancer Res Ther. 14 (Suppl):S490–S493. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kelly AD, Haibe-Kains B, Janeway KA, Hill
KE, Howe E, Goldsmith J, Kurek K, Perez-Atayde AR, Francoeur N, Fan
JB, et al: miRNA paraffin-based studies in osteosarcoma reveal
reproducible independent prognostic profiles at 14q32. Genome Med.
5:22013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heare T, Hensley MA and Dell'Orfano S:
Bone tumors: Osteosarcoma and Ewing's sarcoma. Curr Opin Pediatr.
21:365–372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Braconi C, Henry JC, Kogure T, Schmittgen
T and Patel T: The role of microRNAs in human liver cancers. Semin
Oncol. 38:752–763. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Niu J, Sun Y, Guo Q, Niu D and Liu B:
Serum miR-95-3p is a diagnostic and prognostic marker for
osteosarcoma. Springerplus. 5:19472016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xi M, Cheng L, Hua W, Zhou YL, Gao QL,
Yang JX and Qi SY: MicroRNA-95-3p promoted the development of
prostatic cancer via regulating DKK3 and activating Wnt/β-catenin
pathway. Eur Rev Med Pharmacol Sci. 23:1002–1011. 2019.PubMed/NCBI
|
|
26
|
Turashvili G, Lightbody ED, Tyryshkin K,
SenGupta SK, Elliott BE, Madarnas Y, Ghaffari A, Day A and Nicol
CJB: Novel prognostic and predictive microRNA targets for
triple-negative breast cancer. FASEB J. May 29–2018.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
You H, Ge Y, Zhang J, Cao Y, Xing J, Su D,
Huang Y, Li M, Qu S, Sun F and Liang X: Derlin-1 promotes
ubiquitylation and degradation of the epithelial Na+
channel, ENaC. J Cell Sci. 130:1027–1036. 2017.PubMed/NCBI
|
|
28
|
Varley KE, Gertz J, Roberts BS, Davis NS,
Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A,
et al: Recurrent read-through fusion transcripts in breast cancer.
Breast Cancer Res Treat. 146:287–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian Y, Wong CC, Xu J, Chen H, Zhang Y,
Kang W, Wang H, Zhang L, Li W, Chu ESH, et al: Sodium channel
subunit SCNN1AB suppresses gastric cancer growth and metastasis via
GRP78 degradation. Cancer Res. 77:1968–1982. 2017. View Article : Google Scholar : PubMed/NCBI
|
